AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38594603
Drug: GARD-optimized doses
RxNorm normalized name: Eco-Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GARD-optimized doses with simultaneous integrated boost (SIB) doses of 70 and 60 Gy in 25 fractions to the highest and intermediate radioresistant habitats, while the remaining volume receives standard 50 Gy
Trial: 38594603
Drug: mpMRI taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mpMRI taken between weeks two and three of treatment
Trial: 38594727
Drug: Unsupervised robot-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised robot-assisted therapy
Trial: 38594725
Drug: CBT-I with
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-I with bright light therapy
Trial: 38594737
Drug: Functional-Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional-Cognitive and Sensory Treatment (F-CaST)
Trial: 38594905
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus chemotherapy (Sin+Chemo)
Trial: 38597172
Drug: Low-dose ticagrelor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ticagrelor (60 mg twice a day)
Trial: 38597172
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg once a day)
Trial: 38597214
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG) receiving 8 mg cyproheptadine and 5 mg prazosin ER daily
Trial: 38597214
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG) receiving 12 mg cyproheptadine and 10 mg prazosin ER daily
Trial: 38597399
Drug: Ablation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation plus systemic therapy (AS)
Trial: 38597864
Drug: AT-001 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-001 (selective aldose reductase inhibitor) administered twice daily for 15 months
Trial: 38597988
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg oral THC
Trial: 38598227
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (100 impulses of 0.1mJ/mm/cm2 in gastrocnemius muscle, 3 times weekly for 3 weeks)
Trial: 38598227
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (no shockwaves delivered)
Trial: 38598229
Drug: Guselkumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (subcutaneous injections at FDA-approved dosing schedule for psoriasis over 24 weeks)
Trial: 38598516
Drug: Parsaclisib +
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib + rituximab (Treatment A)
Trial: 38598516
Drug: Parsaclisib +
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib + rituximab + bendamustine (Treatment B)
Trial: 38598516
Drug: Parsaclisib +
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib + ibrutinib (Treatment C)
Trial: 38598710
Drug: Myeloablative consolidation
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative consolidation (for those who completed therapy)
Trial: 38598710
Drug: Nonmyeloablative consolidation
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative consolidation (for those who completed therapy)
Trial: 38599257
Drug: Technology-assisted Web
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Technology-assisted Web App for self-selection of nonprescription statin treatment
Trial: 38599653
Drug: SARS-CoV-2 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccines in IMIDs patients
Trial: 38599653
Drug: SARS-CoV-2 vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccines in healthy controls (HC)
Trial: 38599653
Drug: Post-immunisation anti-RBD
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-immunisation anti-RBD levels <6000 binding antibody units/mL
Trial: 38599799
Drug: Maternal medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal medicines
Trial: 38599800
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral administration of 10,000 IU vitamin D
Trial: 38600278
Drug: High antihypertensive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antihypertensive medication burden (≥3 different classes of prescribed antihypertensive medications)
Trial: 38600278
Drug: High antihypertensive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antihypertensive medication burden in the standard group
Trial: 38600278
Drug: High antihypertensive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antihypertensive medication burden in the intensive group
Trial: 38600471
Drug: binimetinib 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: binimetinib 45 mg BID plus nivolumab 480 mg Q4W
Trial: 38600501
Drug: Pedicled buccal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pedicled buccal periosteal flap for closure of oroantral fistula
Trial: 38600507
Drug: GFH018 5-85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFH018 5-85 mg BID (14d-on/14d-off)
Trial: 38600507
Drug: GFH018 85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFH018 85 mg BID (7d-on/7d-off)
Trial: 38600599
Drug: CPT medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT medication management intervention during hospitalization with follow-up post-discharge and communication with circle of care
Trial: 38601063
Drug: Subsequent infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent infusions of Lu-177-DOTATATE (reduced doses)
Trial: 38601485
Drug: utidelone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: utidelone (40 mg/m2)
Trial: 38601830
Drug: Clavulanic Acid
RxNorm normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clavulanic Acid (CLAV) 500 mg/day
Trial: 38602417
Drug: KIN-3248 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KIN-3248 (5 to 50 mg orally daily)
Trial: 38602618
Drug: Premixed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premixed group (group M): 12 mg of hyperbaric bupivacaine, 20 mcg of fentanyl, and 100 mcg of morphine injected as a single mixture.
Trial: 38602618
Drug: Separate injection
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injection group (group S): Same drugs in separate injections.
Trial: 38602658
Drug: Integrated self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated self-management behaviors (including CGM usage, frequent glucose testing, insulin pump usage, carbohydrate counting application, adjustment of insulin doses, and usage of apps for diabetes management)
Trial: 38603800
Drug: Darvadstrocel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darvadstrocel treatment
Trial: 38604213
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention plus optimal medical therapy
Trial: 38604504
Drug: 1.4 g/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g/kg/d protein emphasizing unprocessed lean beef (high protein experimental group)
Trial: 38604504
Drug: 1.4 g/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g/kg/d protein from mixed food sources (high protein control)
Trial: 38604504
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g total protein/kg body weight/day from mixed food sources (normal protein control)
Trial: 38604815
Drug: GS-4224 (400-1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-4224 (400-1,500 mg once daily)
Trial: 38605166
Drug: FPM-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPM-guided therapy
Trial: 38605166
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (previous therapy)
Trial: 38605438
Drug: Routine screening
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine screening for plasma BKPyV-DNAemia loads monthly until month 9, then every 3 months until 2 years post-transplant (3 years for children)
Trial: 38605438
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of immunosuppression for patients with BKPyV-DNAemia loads >1000 copies/mL or exceeding 10,000 copies/mL, or with biopsy-proven BKPyV-nephropathy
Trial: 38605438
Drug: Experimental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatments (antivirals, vaccines, neutralizing antibodies, and adoptive T cells)
Trial: 38605658
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of psilocybin (25 mg)
Trial: 38605958
Drug: BVAC-C injection
RxNorm normalized name: protein C Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVAC-C injection at 0, 4, 8 weeks (Arm 1)
Trial: 38605958
Drug: BVAC-C injection
RxNorm normalized name: protein C Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVAC-C injection at 0, 4, 8, 12 weeks (Arm 2)
Trial: 38605958
Drug: BVAC-C injection
RxNorm normalized name: protein C Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVAC-C injection at 0, 4, 8, 12 weeks with topotecan at 2, 6, 10, 14 weeks (Arm 3)
Trial: 38606105
Drug: DNAJB1-PRKACA fusion-based
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNAJB1-PRKACA fusion-based neoepitope vaccine Fusion-VAC-XS15 combined with anti-PD-L1 antibody atezolizumab
Trial: 38606105
Drug: Anti-PD-L1 antibody
RxNorm normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-L1 antibody atezolizumab
Trial: 38606621
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) titration during DISE
Trial: 38606776
Drug: SingHypertension intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SingHypertension intervention (clinician training, subsidized medications, nurse-delivered motivational conversations, telephone follow-ups)
Trial: 38606777
Drug: Apilimod dimesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apilimod dimesylate 125 mg twice daily for 12 weeks
Trial: 38606958
Drug: RSVpreF (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF (240 µg with or without aluminum hydroxide)
Trial: 39382718
Drug: pembrolizumab-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab-chemotherapy
Trial: 38608150
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS)
Trial: 38608658
Drug: Pirfenidone (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (escalated from 3×1 to 3×3 capsules of 267 mg/day within 3 weeks for 12 months)
Trial: 38608691
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (240 mg every 2 weeks)
Trial: 38608691
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (NIVO3 plus IPI1: 3 mg/kg every 2 weeks plus 1 mg/kg every 6 weeks)
Trial: 38608691
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (NIVO1 plus IPI3: 1 mg/kg every 3 weeks plus 3 mg/kg every 3 weeks for four cycles then nivolumab 240 mg every 2 weeks)
Trial: 38609316
Drug: Elotuzumab administered
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab administered starting on day 4 post-ASCT and then every 28 days until 1 year post-ASCT, combined with autologous lymphocyte infusion and lenalidomide maintenance (cycles 4-12).
Trial: 38609316
Drug: Elotuzumab and
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab and autologous lymphocyte infusion post-ASCT.
Trial: 38983921
Drug: Remimazolam-based total
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam-based total intravenous anesthesia
Trial: 38609987
Drug: Maytenus senegalensis
RxNorm normalized name: Khaya senegalensis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maytenus senegalensis (800 mg every 8 hours for 4 days)
Trial: 38610031
Drug: Pamiparib 40
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 40 mg twice daily every 3 weeks for up to 1 year or until disease progression
Trial: 38610034
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation with ProPrems® (Bifidobacterium infantis, Bifidobacterium lactis, and Streptococcus thermophilus) diluted in 3 mL breastmilk per day until gestational week 34
Trial: 38610034
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 g maltodextrin powder) diluted in 3 mL breastmilk per day until gestational week 34
Trial: 38610138
Drug: Staff-facilitated telemedicine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staff-facilitated telemedicine model for HCV treatment initiation
Trial: 38610925
Drug: Neo-adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant systemic therapy (NAS) with immunotherapy (anti-PD-1, combination anti-CTLA-4 and anti-PD-1)
Trial: 38610925
Drug: Pembrolizumab as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab as NAS therapy (3 doses)
Trial: 38610925
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipilimumab + nivolumab as NAS therapy
Trial: 38610950
Drug: sHLA-G levels
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sHLA-G levels in CIN before starting IMQ application
Trial: 38611082
Drug: Transperineal Laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transperineal Laser Ablation (TPLA) treatment, details on dosage and duration not available
Trial: 38611595
Drug: Metabolomic analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolomic analysis at end of induction treatment (D33)
Trial: 38613322
Drug: Perioperative immunonutrition
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative immunonutrition (IMN) with oral supplementation enriched with arginine, omega-3 fatty acids, and dietary nucleotides (Group 2)
Trial: 38613545
Drug: Flecainide acetate
RxNorm normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flecainide acetate oral inhalation solution (FlecIH), single dose administered via oral inhalation over 8 minutes in a supervised medical setting.
Trial: 38613938
Drug: Low PPI
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low PPI (< 1.5) and Low Hb (< 9.7 g/dL)
Trial: 38614279
Drug: 60 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 Gy in 8 fractions (stereotactic body radiation therapy)
Trial: 38614447
Drug: bCBCT augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bCBCT augmented with intranasal oxytocin (40 international units administered 30 min before each session)
Trial: 38614447
Drug: bCBCT augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bCBCT augmented with intranasal oxytocin
Trial: 38614631
Drug: Euvichol-S (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euvichol-S (two 1.5 mL doses)
Trial: 38614954
Drug: TBE vaccine
RxNorm normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBE vaccine (0.5-mL for adults, 0.25-mL for pediatric) administered at 3 visits.
Trial: 38615067
Drug: Letermovir 480
RxNorm normalized name: letermovir 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir 480 mg daily orally for 28 weeks
Trial: 38615070
Drug: Baseline hemagglutination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline hemagglutination antibody inhibition
Trial: 38615472
Drug: Temozolomide 75
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 75 mg/m² given every other week (one week on/one week off)
Trial: 38615472
Drug: Temozolomide 75
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 75 mg/m²
Trial: 38615673
Drug: Intramuscular 85
RxNorm normalized name: 85 strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (Group A)
Trial: 38615673
Drug: Intramuscular 85
RxNorm normalized name: 85 strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional topical ocular administration of CTH522 (Group B)
Trial: 38615673
Drug: Intramuscular 85
RxNorm normalized name: 85 strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional intradermal administration of CTH522 (Group C)
Trial: 38615673
Drug: Intramuscular 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 15 μg CTH522-CAF01, two boosters at day 28 and 112 (Group D)
Trial: 38615673
Drug: Intramuscular 85
RxNorm normalized name: 85 strontium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 85 μg CTH522-CAF09b, two boosters at day 28 and 112 (Group E)
Trial: 38615673
Drug: Intramuscular placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular placebo (Group F)
Trial: 38615899
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise training (RET), 16-week, twice-weekly, whole-body intervention
Trial: 38616308
Drug: Dasatinib plus
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib plus low-intensity chemotherapy for one month followed by dasatinib monotherapy for two months
Trial: 38616308
Drug: Dasatinib-based low-intensity
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib-based low-intensity chemotherapy
Trial: 38616411
Drug: BPL-003 (5-methoxy-DMT)
RxNorm normalized name: 2-methoxy-5-chloroprocainamide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BPL-003 (5-methoxy-DMT) at doses of 1-12 mg
Trial: 38616411
Drug: BPL-003 (5-methoxy-DMT)
RxNorm normalized name: 2-methoxy-5-chloroprocainamide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BPL-003 (5-methoxy-DMT) at doses of 10 and 12 mg
Trial: 38616438
Drug: RSVpreF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVpreF vaccine (120-µg injection)
Trial: 39046635
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of natalizumab
Trial: 39046635
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of natalizumab
Trial: 38617387
Drug: Therapist-guided internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-delivered cognitive behavioural therapy (ICBT) for 12 weeks
Trial: 38617599
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg bid plus spartalizumab 300 mg q3w
Trial: 38617784
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus 30 minutes before incision, followed by continuous infusion of 3.0 mg/kg/hour until 2 hours after skin closure)
Trial: 38618202
Drug: GST-HG171 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG171 (150 mg) plus Ritonavir (100 mg)